The Experts below are selected from a list of 306 Experts worldwide ranked by ideXlab platform
S Thoelen - One of the best experts on this subject based on the ideXlab platform.
-
the immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Guido Moens, Geert Lerouxroels, S ThoelenAbstract:ABstract Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20–60 years old non-responders (titre P =0.03). One month after the second dose this was 58 and 81%, respectively ( P P P
-
The immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non-responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Geert Leroux-roels, Gabriël Moens, S ThoelenAbstract:Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20-60 years old non-responders (titre
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.
Isabelle Desombere - One of the best experts on this subject based on the ideXlab platform.
-
the immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Guido Moens, Geert Lerouxroels, S ThoelenAbstract:ABstract Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20–60 years old non-responders (titre P =0.03). One month after the second dose this was 58 and 81%, respectively ( P P P
-
The immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non-responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Geert Leroux-roels, Gabriël Moens, S ThoelenAbstract:Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20-60 years old non-responders (titre
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.
Nehama Linder - One of the best experts on this subject based on the ideXlab platform.
-
Immunogenicity of <B>HepatitisB> B Vaccine in preterm infants
Archives of Disease in Childhood-fetal and Neonatal Edition, 1998Co-Authors: Orna Blondheim, David Bader, Martha Abend, Marina Peniakov, Danny Reich, I Potesman, Rachel Handsher, Ifat Gidoni, Nehama LinderAbstract:Aim—To assess the immunogenicity of <B>HepatitisB> B Vaccine in preterm and term infants, given in a sequence of three doses Beginning soon after Birth. Method—The immunogenicity of <B>HepatitisB> B Vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after Birth, and compared with that in 46 term infants. Titres of <B>HepatitisB> B antiBodies were determined one to two months after the third Vaccine. The significance of the diVerences Between the term and preterm groups was determined using Student’s t test. Results—A similar proportion of infants in Both preterm and term groups attained protective titres of <B>HepatitisB> B antiBodies (88.7% vs 93.4%, respectively; p=NS). However, the term infants had a higher geometric mean titre of antiBodies after the third Vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p
P Jacques - One of the best experts on this subject based on the ideXlab platform.
-
the immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Guido Moens, Geert Lerouxroels, S ThoelenAbstract:ABstract Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20–60 years old non-responders (titre P =0.03). One month after the second dose this was 58 and 81%, respectively ( P P P
-
The immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non-responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Geert Leroux-roels, Gabriël Moens, S ThoelenAbstract:Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20-60 years old non-responders (titre
Geert Leroux-roels - One of the best experts on this subject based on the ideXlab platform.
-
The immunogenicity and reactogenicity profile of a candidate <B>HepatitisB> B Vaccine in an adult Vaccine non-responder population
Vaccine, 2002Co-Authors: P Jacques, J. Dewijngaert, M. Wettendorff, Isabelle Desombere, Geert Leroux-roels, Gabriël Moens, S ThoelenAbstract:Approximately 5% of Vaccinees display an inadequate response after the administration of the standard three dose <B>HepatitisB> B Vaccine. A new <B>HepatitisB> B Vaccine (HBsAg/AS04) formulated with the adjuvant AS04 which contains 3′-deacylated monophosphoryl lipid A (3D-MPL) and alum has Been developed. AS04 enhances the immune response which may Be Beneficial to non-responders. In a single-Blind, randomised study, we tested the immunogenicity and reactogenicity of the new Vaccine with that of commercially estaBlished <B>HepatitisB> B Vaccine, Both on a 0, 1, 6 months schedule in 20-60 years old non-responders (titre
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.
-
A <B>HepatitisB> B Vaccine formulated with a novel adjuvant system.
Vaccine, 2000Co-Authors: F. Ambrosch, Isabelle Desombere, Geert Leroux-roels, Gerhard Wiedermann, M. Kundi, Nathalie Garçon, C. Thiriart, Moncef Slaoui, S ThoelenAbstract:Although more than 95% of the vaccinated population responds to the currently licensed Vaccines against <B>HepatitisB> B, some groups were found to Be low responders. Lipid A as adjuvant, through its aBility to activate macrophages, might improve humoral as well as cellular immune response. Therefore we evaluated the profile of a <B>HepatitisB> B Vaccine with the new adjuvant system SBAS4. 150 young adults were enrolled and randomized into three groups: one received the SBAS4 <B>HepatitisB> B Vaccine, the second Engerix-BTM and the third a <B>HepatitisB> B Vaccine with an alternative formulation on alum. Vaccinations were at 0 and 6 months. The Vaccine was well tolerated. At month 7 all Vaccinees were protected But with significant differences in GMTs Between groups: 13,271 mIU/ml for the SBAS4 group versus 1203 and 1823 mIU/ml. Hence the <B>HepatitisB> B Vaccine with the new adjuvant system is more immunogenic compared to the other Vaccines containing the same antigen and could Be suitaBle for a two dose schedule.